Professional Documents
Culture Documents
Arterial hypertension
Sofie Brouwers, Isabella Sudano, Yoshihiro Kokubo, Elisabeth M Sulaica
Arterial hypertension is the most important contributor to the global burden of disease; however, disease control Published Online
remains poor. Although the diagnosis of hypertension is still based on office blood pressure, confirmation with out- May 18, 2021
https://doi.org/10.1016/
of-office blood pressure measurements (ie, ambulatory or home monitoring) is strongly recommended. The definition S0140-6736(21)00221-X
of hypertension differs throughout various guidelines, but the indications for antihypertensive therapy are relatively
Department of Cardiology,
similar. Lifestyle adaptation is absolutely key in non-pharmacological treatment. Pharmacologically, angiotensin- Cardiovascular Center Aalst,
converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, and diuretics are the first- OLV Hospital Aalst, Aalst,
line agents, with advice for the use of single-pill combination therapy by most guidelines. As a fourth-line agent, Belgium (S Brouwers MD);
Department of Experimental
spironolactone should be considered. The rapidly evolving field of device-based therapy, especially renal denervation, Pharmacology, Faculty of
will further broaden therapeutic options. Despite being a largely controllable condition, the actual rates of awareness, Medicine and Pharmacy, Vrije
treatment, and control of hypertension are disappointingly low. Further improvements throughout the process of Universiteit Brussel, Brussels,
patient screening, diagnosis, treatment, and follow-up need to be urgently addressed. Belgium (S Brouwers);
University Heart Center,
Cardiology, University Hospital
Epidemiology China, it was found that 44·7% of patients were Zurich, University of Zurich,
Hypertension is one of the most important modifiable hypertensive and only 44·7% of those with hypertension Zurich, Switzerland
risk factors for cardiovascular disease and one of were aware of their condition.4 Even more compelling, (I Sudano MD); Department of
Preventive Cardiology,
the largest contributors to morbidity and mortality only 30·1% of patients were prescribed antihypertensive National Cerebral and
worldwide. In a systematic analysis done for the Global agents and 7·2% had their blood pressure controlled. Cardiovascular Center, Suita,
Burden of Disease Study 2017, high systolic blood When standardised for age and sex, hypertension had Japan (Y Kokubo MD); Institute
pressure (SBP) was the leading risk factor for mortality rates of 37·2% for prevalence, 36·0% for awareness, of Cardiovascular and Medical
Sciences, University of
(10·4 million deaths) and disability-adjusted life-years 22·9% for treatment, and 5·7% for control. Glasgow, Glasgow, UK
(218 million).1 In a study including 8·69 million In the African population, a systematic review and (Y Kokubo); Pharmacy Practice
participants from 154 countries, it was estimated that meta-analysis of data from 25 studies showed a pooled and Translational Research,
between 1990 and 2015, the number of participants with prevalence of 5·5% in children and adolescents with University of Houston College
of Pharmacy, Houston, TX, USA
an SBP of at least 110–115 mm Hg increased from elevated blood pressure (≥95th percentile) and of 12·7% (E M Sulaica PharmD)
73·1% to 81·3%, and those with an SBP of at least in children and adolescents with slightly elevated blood Correspondence to:
140 mm Hg increased from 17·3% to 20·5%.2 Add pressure (≥90th percentile and <95th percentile).5 Prof Sofie Brouwers, Department
itionally, the estimated rate of annual deaths associated Increased body-mass index was largely associated with of Cardiology, Cardiovascular
with an SBP of at least 110–115 mm Hg increased by prevalence of elevated blood pressure, which was Center Aalst, OLV Hospital Aalst,
Aalst 9300, Belgium
7·1% from 1356 per million, and deaths associated with six times higher in children and adolescents (aged sofie.brouwers@olvz-aalst.be
an SBP of at least 140 mm Hg increased by 8·6% from 2–19 years) with obesity than in age-matched individuals
979 per million. without obesity. From a public health standpoint, it is
According to the 2019 May Measurement Month
campaign initiated by the International Society of
Hypertension (ISH), involving more than 1·5 million Search strategy and selection criteria
individuals screened from 92 countries, 32·0% had never We searched PubMed and MEDLINE for articles published
had their blood pressure measured and 34·0% had been from Jan 1, 2010, to Oct 25, 2020. We used the search terms
diagnosed with hypertension, among whom 58·7% were “blood pressure”, “hypertension”, “arterial hypertension”,
aware that they had hypertension and 54·7% were on in combination with the terms “guidelines”, “chronotropy”,
antihypertensive medications.3 In patients with hyper “resistant hypertension”, “diabetes”, “ambulatory blood
tension, 31·7% had blood pressure readings below pressure monitoring”, “home blood pressure measurement”,
140/90 mm Hg and 23·3% below 130/80 mm Hg. Of “digital health”, “mobile health”, “lifetime risk”, “prospective
patients on at least one antihypertensive, 57·8% had blood studies”, “epidemiology”, “population”, “lifetime blood
pressure readings below 140/90 mm Hg and 28·9% below pressure”, “diet”, “lifestyle”, “periodontitis”, “inflammation”,
130/80 mm Hg. Of patients taking antihypertensive “renin-angiotensin system”, “angiotensin-(1–7)”, “novel
medications, half were single-drug users. Since May, 2017, coronavirus disease 2019”, “genome-wide association”,
more than 4·2 million participants had their blood and “global”. We largely selected publications from the past
pressure measured and almost 1 million adults with 5 years, but did not exclude commonly referenced and highly
hypertension were untreated or undertreated. regarded older publications. We also searched the reference
Globally, hypertension awareness varies, with at least lists of articles identified by this search strategy and selected
70% of people with hypertension from the Americas and those we judged relevant. Review articles and book chapters
Europe being aware of their condition compared with are cited to provide readers with more details and references
only up to 40% of patients from south Asia and sub- than this Seminar has room for.
Saharan Africa. In a sample of 1·7 million adults in
essential to prevent obesity to improve hypertension, systemic inflammation, leading to increased blood
given that the factors contributing to increased body- pressure.
mass index are applicable to Africans spanning from Interactions between genes and the environment
childhood5 to adulthood.6 The meta-analysis also found illustrate the benefit of common lifestyle modifications
that elevated blood pressure was more pervasive in rural based on the recommendations of hypertension guide
areas than in urban areas; however, no differences in lines, which consist of the following elements: weight
prevalence were observed between boys and girls.5 reduction, a healthy diet, dietary sodium reduction,
Another study showed that the prevalence of hyper increased physical activity, and the cessation of smoking
tension is higher in people of African origin than in and excessive alcohol consumption.24
those of European origin.7 As well as these environmental factors, a complex genetic
In a study done in the USA, the strongest increase background has a role, which research is continuing to
from ideal blood pressure to pre-hypertension occurs at expand on.25 Data from genome-wide association studies
age 8 years for boys of White ethnicity, and at age on blood pressure traits (systolic, diastolic, and pulse
25 years for young African Americans, illustrating pressure) have led to greater understanding of important
how heterogeneity in blood pressure starts appearing loci involved in blood pressure. The discovery of novel loci
at a young age.8 Pre-emptive prophylaxis beginning has clarified new mechanisms of blood pressure regulation
in early adulthood might be necessary to prevent and the association between blood pressure and lifestyle.26,27
pre-hypertension and hyperten sion, as well as the
development of associated racial, ethnic, and gender The renin–angiotensin–aldosterone system (RAAS) and
disparities that could be variably interpreted.9,10 An COVID-19
analysis of the original cohort in the Framingham Heart Throughout the COVID-19 pandemic, a key consideration
Study showed that individuals in the community of hypertension pathophysiology and management has
generally maintained SBP below 120–125 mm Hg; been the effect of SARS-CoV-2 on the RAAS system.
however, when SBP began to rise above this range, it SARS-CoV-2 has been proposed to gain entry into cells
increased relatively rapidly towards overt hypertension.11 through endocytosis, by binding to angiotensin-
This tendency was consistent, regardless of whether or converting enzyme (ACE) 2.28 This theory has led to
not hypertension appeared early or late in life. discussion around discontinuing ACE inhibitors or
Interestingly, a large-scale analysis of individual patient angiotensin receptor blockers (ARBs) due to concern
trajectories provided evi dence that lifetime SBP and for ACE2 upregulation and subsequent increase in
diastolic blood pressure were most elevated at least SARS-CoV-2 virility. To our knowledge, clinical studies
14 years before death, and subsequently decreased until in this population are observational in nature and an
death.12 64·0% of the patients included in this analysis association between use of ACE inhibitors or ARBs and
had SBP decreases of at least 10 mm Hg. This reduction increased SARS-CoV-2 infection or severity of COVID-19
was present in all individuals, including those who did has not been found.29–35 Multiple prospective, ongoing,
not receive anti hypertensive treatment, and was most randomised trials will evaluate the outcomes of ACE
pronounced in older patients and in patients treated for inhibitor or ARB use or discontinuation in the setting of
hypertension, dementia, heart failure, or late-life weight COVID-19 (NCT04591210; NCT04353596). Interestingly,
loss. SARS-CoV-2 infection has also been shown to result
in ACE2 downregulation after initial binding to recep
Pathophysiology tors.28,36 ACE2 is important in counteracting effects of
Hypertension can be classified as essential or secondary, the RAAS system and, thus, there is also discussion
with most patients having essential hypertension.13 around the possible benefits of RAAS attenuation in
The cause of hypertension is multifactorial in nature, with COVID-19.37 Current recommendations are to avoid
environment, genetics, and social determinants having discontinuing RAAS inhibitors when they are clinically
the potential to contribute to its development.13 A better indicated and especially if they are the cornerstone of the
understanding of the interplay between these components therapy, like in heart failure and ischaemic heart
has continued to unfold.14 disease.37–39
Increasing knowledge has also been gathered on the
pathophysiology of hypertension. Besides the traditional Diagnosis
environmental factors (eg, obesity, physical inactivity, Blood pressure measurements
excessive sodium intake, and chronic stress), preterm Accurate and reliable blood pressure measurements
birth or low birthweight,15,16 and air and noise pollution,17,18 are essential for the diagnosis of hypertension. Blood
have also been shown to contribute to the development pressure changes constantly in response to endogenous
of the condition. Additionally, immune mechanisms and factors and exogenous stimuli; therefore, standardisation
systemic inflammation have proven to be important in is essential for an accurate measurement.40 Unfortunately,
the pathogenesis of hypertension.19,20 In particular, gut the problem of unstandardised measurements has
microbiota21,22 and periodontitis23 seem to play a role in persisted for decades, despite efforts in education and
simplification of the measurement process. The wide consensus on definitions, thresholds and targets, and
spread availability of non-validated blood pressure devices demonstration that interventions mitigating blood
might lead to incorrect diagnosis41 and management.42 pressure variability improve outcomes.
The Lancet Commission on hypertension43,44 aimed to
identify key actions for improving global management Classification
of blood pressure, both at population and individual The definition of arterial hypertension is based in all
levels. To obtain correct blood pressure measurements, available guidelines on office blood pressure.48–50 Although
trained observers using standardised methodologies are the definition of arterial hypertension differs between the
needed.45–47 Multiple readings over time are required to 2018 European Society of Cardiology (ESC)–European
estimate blood pressure, allowing for regression to the Society of Hypertension (ESH) guidelines,48 the 2017
mean, and mitigating risk of obtaining elevated readings American College of Cardiology (ACC)–American Heart
secondary to white-coat hypertension.43,48 The most used Association (AHA) guidelines,49 and the 2020 ISH
methods for measuring blood pressure in a clinical care guidelines (table 1),50 the indications for antihypertensive
setting are either direct (ie, intra-arterial) or indirect (ie, therapy are similar: patients with a blood pressure of
cuff-based). Indirect blood pressure measurements are at least 140/90 mm Hg should be treated if the cardio
typically done via auscultation or with a semi-automated vascular risk is high or if signs of target organ damage are
or fully automated device, which most often uses the present. In patients with grade 1 hypertension (definitions
oscillometric technique. Use of automated measurements vary depending on the guideline),48,49 at low-to-moderate
might avoid observer bias; however, there are situations cardiovascular risk, and without evidence of hypertension-
(eg, increased arterial stiffness or arrhythmias) in which mediated organ damage, drug treatment to lower blood
use of automated devices can lead to error. Although office pressure is recommended if the patient remains
blood pressure is still the gold standard for diagnosing hypertensive after a period of lifestyle intervention.58
arterial hypertension, contemporary guidelines recom All guidelines agree that many blood pressure
mend confirming the diagnosis with out-of-office mea measurements are necessary to correctly diagnose
surements, such as ambulatory or home blood pressure arterial hypertension.48–50 In all patients who have an
monitoring.48–51 24 h ambulatory and home blood pressure elevated office blood pressure, diagnosis should be
monitoring were shown to be superior to office mea confirmed by use of out-of-office blood pressure
surements for prediction of cardiovascular events and are measurements (ie, home or ambulatory blood pressure
ideal for follow-up monitoring in the long term.48–50 monitoring). Out-of-office measurements are also useful
Unattended blood pressure measurements eliminate for diagnosing white coat or masked hypertension. It
patient–observer interaction, minimise patient anxiety, should be noted that values classified as normal are
and reduce observer error associated with manual different for office and out-of-office measurements
measurement.52 This method was used for the first time (table 2).
in the SPRINT trial.53 On average, unattended SBP is
10 mm Hg lower than the office sphygmomanometer
Systolic and diastolic blood pressure,
or oscillometric value (depending on baseline blood mm Hg
pressure), and should not be used interchangeably with
American College of Cardiology–American Heart Association49
other office measurements.54 Large randomised con
Normal <120 and <80
trolled trials exploring use of unattended blood pressure
Increased 120–129 and <80
measurements for predicting hypertension-mediated
organ damage, as well as the correlation between this Stage 1 130–139 or 80–89
method and cardiovascular morbidity and mortality, are Stage 2 ≥140 or ≥90
Snoring, daytime sleepiness, morning headache, irritability, increase in Obstructive sleep apnoea Screening questionnaire,
neck circumference, obesity, peripheral oedema polysomnography
American College of Cardiology– European Society of Cardiology– National Institute for International Society of
American Heart Association European Society of Health and Care Hypertension 202050
201749 Hypertension 201848 Excellence 201967
Sodium <1500 mg/day (ideal) Limit to up to 2000 mg/day Encourage a reduction Avoid foods with high salt content
consumption in sodium intake
Diet DASH High in fruits and vegetables, Encourage a healthy DASH diet; high in fruits and vegetables,
low-fat dairy, fish, whole grains; diet polyunsaturated fats, and dairy; low in foods
low in red meat and saturated fats high in sugar, saturated fats, and trans fats
Alcohol ≤2 standard drinks* per day for <14 units/week for men†; Encourage a reduction ≤2 standard drinks‡ per day for men;
consumption men; ≤1 standard drinks* per day <8 units/week for women† in intake if excessive ≤1·5 standard drinks‡ per day for women
for women
Physical Aerobic exercise: 90–150 mins/ Aerobic exercise for ≥30 mins/day Encourage regular Moderate aerobic activity for 30 mins/day
activity week; dynamic resistance training: ≥5 days/week exercise ≥5 days/week or high-intensity interval
90–150 mins/week training; resistance or strength exercises
2–3 days/week
Weight Target ideal bodyweight Avoid BMI >30 kg/m² or waist NA Ethnic-specific BMI and waist
reduction circumference >102 cm in men or circumference cutoffs to avoid obesity
>88 cm in women
DASH=dietary approach to stop hypertension. NA=not applicable. BMI=body-mass index. *One standard drink contains roughly 14 g of pure alcohol, which is typically found in
12 oz of regular beer (usually about 5% alcohol), 5 oz of wine (usually about 12% alcohol), and 1·5 oz of distilled spirits (usually about 40% alcohol). †1 unit is equal to 125 mL of
wine or 250 mL of beer. ‡One standard drink is equivalent to 10 g of alcohol.
or thiazide or thiazide-like diuretic) at maximally tolerated control in this age group. Decisions for antihypertensive
doses.48–50,67 Options for add-on therapy include miner management should be all encompassing, not solely based
alocorticoid receptor antagonists, β blockers, and on age, and take into account considerations such as
α1 blockers. A meta-analysis found mineralocorticoid patient comorbidities, other medications that can affect
receptor antagonists to be the most effective add-on blood pressure, and level of frailty.
therapy for resistant hypertension. Compared with Although not approved for hypertension, SGLT2
doxazosin and bisoprolol, a significantly greater reduction inhibitors have been found to decrease SBP by around
in SBP was achieved with spironolactone in a double- 4 mm Hg.82 The mechanism for this reduction is thought
blind, placebo-controlled, crossover trial.76,77 Spironolactone to be secondary to inhibition of sodium reuptake and
should be considered as a fourth-line agent for hyper subsequent sodium excretion.83 This effect of SGLT2
tension in the absence of contraindications. inhibitors is something to consider when managing
There might be instances in which reducing a medication patients with diabetes and hypertension; although not an
dose or even discontinuing medication altogether could be antihypertensive agent, its antihypertensive effects could
considered in patients with blood pressures below the allow for maximisation of blood pressure control in
optimal target, or in the case of adverse events. A systematic conjunction with diabetes management.
review found that factors such as monotherapy and lower
blood pressure before withdrawal were both predictors of Device-based treatment
success with regard to blood pressure control.78 The blood Various device-based therapies have emerged, such as
pressure of approximately 40% of patients was found to renal denervation, carotid baroreceptor stimulation,
still be controlled 1 year after medication withdrawal. creation of an arteriovenous fistula, or endovascular
Regardless of why medications are reduced in dose or are carotid body modification, and principally target the
discontinued, continual follow-up and monitoring for treatment of resistant or difficult-to-treat hypertension.
return of hypertension is paramount. Additionally, abrupt Renal denervation is the treatment modality with the
withdrawal of medications, particularly β blockers or most available data to date. The principle of this therapy
clonidine, should be avoided due to risk of deleterious is to eliminate sympathetic nerves around the renal
effects. Further research is needed to identify ideal patients artery, resulting in lower renal efferent and afferent
for whom to consider withdrawal, and to assess the long- sympathetic nervous activity and ultimately lower blood
term outcomes. pressure. The first results of renal denervation were
A 2020 publication longitudinally evaluating blood obtained with devices that used radiofrequency appli
pressure differences between sexes found that women cation in the open-label SYMPLICITY HTN-184 and
had a more precipitous increase in blood pressure than SYMPLICITY HTN-285 trials, along with several case
men, starting in early adulthood.79 These results warrant series and observational studies. Despite showing
further exploration; however, they have not yet led to safety, the SYMPLICITY HTN-386 trial was unable
changes in hypertension management between sexes. In to show efficacy of renal denervation with a radio
general, sex-specific management should be considered, frequency catheter over sham treatment in patients with
especially in pregnant women. ACE inhibitors, ARBs, severe resistant hypertension on multiple medications.48
and direct renin inhibitors are contraindicated due to However, post-hoc analyses of the SYMPLICITY HTN-3
risk of foetal injury and death. Appropriate agents for trial underlined important trial limitations to consider,
hypertensive management include methyldopa, labetalol, including trial patient selection, differences in adherence
or nifedipine.48,49 Despite how women aged 65 years and to antihypertensive medications between the treatment
older are more likely to have higher blood pressure later groups, a higher use of antihypertensive drugs in the
in life than are men, there is currently no distinction in sham group, and technical failure in carrying out renal
pharmacological management between the two sexes.70 denervation in the intervention group (eg, an insufficient
It is well known that hypertension prevalence increases number of ablations, ablation in the distal part of the
with age. It was found that more than 50% of patients with artery and limited to the main renal artery, and first-time
hypertension aged 80 years and older in the USA have performance of renal denervation for some operators).
uncontrolled hypertension.80 Elevated blood pressure has These limitations led to a revision of renal denervation
been associated with poor cardiovascular outcomes in technology and technique. Since SYMPLICITY HTN-3,
older patients, yet questions of how much to lower SBP by several novel, sham-controlled studies have been done or
in this population continue to arise.81 In a subgroup are underway. The SPYRAL HTN-OFF MED,87,88 SPYRAL
analysis from the SPRINT trial, patients aged 75 years and HTN-ON MED,89 and RADIANCE-HTN SOLO90 trials
older were found to benefit more from intensive blood showed significant and consistent reductions in blood
pressure treatment (SBP <120 mm Hg) than from stan pressure (both office and ambulatory) in patients with
dard treatment (SBP <140 mm Hg). Current guidelines and without concomitant antihypertensive use. The
recommend that providers work with patients to reach SPYRAL HTN-OFF MED trial showed catheter-based
blood pressure targets in patients aged 65 years and older, renal denervation to be superior to a sham procedure,
given that data indicate benefits from blood pressure with the intervention safely lowering blood pressure in
the absence of antihypertensive medications.88 Possible pressure control is therapeutic inertia, which includes
response indicators to renal denervation therapy can be failure to start or intensify antihypertensive therapy,
divided into patients with increased arterial stiffness and despite not having blood pressure under control. This
those with increased neurogenic activity.91 Consideration conundrum can consequently lead to additional years of
of these factors and use of the revised techniques will exposure to high blood pressure. When the decision is
considerably improve future studies and ultimately made to start antihypertensive treatment, the patient
expand our knowledge on renal denervation. Data should have regularly scheduled follow-ups in the early
showing efficacy of renal denervation for hypertension phase that continue until blood pressure is controlled
in patients without pharmacological therapy led to under stable treatment. Another major concern in
discussion about device treatment of hypertension as a unsuccessful treatment is non-adherence. This common
possible area of a shared decision making approach. and persistent problem should be addressed from the
Less evidence is available on the effect of carotid start of treatment and throughout its course. From early
baroreceptor stimulation and endovascular carotid body on, it is important to extensively counsel the patient and
modification. Both techniques aim to reduce blood their support system about the clinical reasoning for
pressure through reduction of sympathetic tone. The treatment and the long-term risk of elevated blood
first-generation carotid baroreceptor stimulation device pressure. The sharing of responsibility for a patient’s
reduced blood pressure in controlled and uncontrolled cardiovascular health is pivotal to improve patient
clinical trials. Currently, there are no controlled clinical investment in their health, diet, lifestyle, and medication
trials proving efficacy in blood pressure reduction for the compliance. In addition, obtaining blood pressure targets
second-generation carotid sinus stimulator.92 Some (mostly in the short term will reinforce the patient’s confidence
uncontrolled) studies suggest that other techniques, such in their treatment and promote persistent blood pressure
as baroreflex amplification and carotid body modulation, control to increase the likelihood of cardiovascular
might lead to blood pressure reduction in patients with benefit. Simplified and tailored treatment regimens (eg,
difficult-to-treat hypertension. However, more evidence considering costs, use of single-pill combinations, etc)
regarding the safety and efficacy of these techniques from will be of great importance for treatment success.96,97
large, randomised, sham-controlled trials is needed before The greatest challenge beyond the short-term manage
implementing baroreflex amplification and carotid body ment of hypertension is maintaining therapy adherence.
modulation into routine clinical practice.93
Furthermore, the creation of an iliac arteriovenous Health-care system
anastomosis to safely reduce blood pressure in patients
Awareness
with uncontrolled hypertension was assessed.94 The
ROX CONTROL HTN study95 evaluated this intervention
with the novel arteriovenous ROX Coupler (ROX
Screening
Medical; San Clemente, CA, USA). This small study, Treatment
Simplified and
involving 44 patients in the treatment group and tailored
39 patients in the standard care group, found that
creation of an arteriovenous anastomosis was associated
with a significant reduction in blood pressure. Due to
Sex, age, ethnicity, and
adverse events, including the development of venous concomitant disease
stenosis, the pivotal ROX HTN 2 trial was stopped.
The 2018 ESC–ESH guidelines do not recommend use
of device-based therapies for the routine treatment of Socioeconomic
hypertension, unless in the context of clinical studies status, lifestyle,
and behaviour
and randomised controlled trials.48 Nevertheless, device- Diagnosis Follow-up
based therapy for hypertension is a fast-moving field and • Blood pressure monitoring,
compliance, treatment
newly emerging data are now becoming available, which • Strongly supported by
could change this recommendation. digital health
Education
Timescales of treatment and follow-up
Hypertension Primary Patient
A short-term, medium-term, and long-term timescale Pharmacist
clinic care*
Patient
environment
can be distinguished in the course, challenges, and
treatment of arterial hypertension. A timely diagnosis, Figure 2: Key contributors in the process of blood pressure control and therapy adherence
which can only be obtained by regular blood pressure The patient is an integral part of their environment, and all interactions between the patient and various actors
measurements throughout an individual’s lifetime, is within the health-care system fall within this environment. The left side of the figure represents interactions
during the screening and diagnosis phase, whereas the right side represents the treatment and follow-up phase,
crucial in the management of hypertension. Additionally, containing many factors involved in therapy adherence. Treatment and follow-up are inseparably linked. The role
timely initiation of therapy is essential. Unfortunately, an of the pharmacist and hypertension clinic can vary widely among different health-care settings. *General
important issue in improving population-wide blood practitioner or community health worker.
Non-adherence is particularly frequent in patients with brain aminopeptidase A inhibitor, firibastat, is currently
apparently resistant hypertension and contributes to undergoing phase 2 (NCT03715998), and will soon
poor cardiovascular prognosis. Monitoring of adherence begin phase 3 (NCT04277884) trials.103 Upcoming trials
should be done routinely through open and non- will evaluate firibastat versus ramipril after myocardial
accusatory communication between the clinician and infarction (NCT03715998), and firibastat versus placebo
patient. Furthermore, indirect methods (eg, pill counts, in patients with uncontrolled primary hypertension.
tracking prescription refills, and self-reports) and direct Another promising pathway for new treatment targets
methods (eg, detection of drugs or their metabolites in is the protective arm of the RAAS (eg, ACE2, angiotensin
urine or plasma) have been developed.98 A continuous [1–7], AT2 receptor, Mas receptor axis), which has a
effort between patients and their health-care team needs counter-regulatory role in opposing AT1 receptor-
to be made to maintain, improve, and regain therapy mediated actions by mediating tissue protective and
adherence. regenerative actions (eg, vasodilation, natriuresis, and
Arterial hypertension is a chronic disease that requires anti-inflammatory, antiproliferative, and antifibrotic
regular follow-up in the long term. Management is a responses).104 Sex differences have been established in
multidisciplinary matter that should involve the primary the different mechanisms of action of the RAAS.105
health-care physician, hypertension specialist, and phar However, there are still important gaps in the scientific
macist, among other caregivers of the patient (figure 2). knowledge on the preclinical and clinical level of sex
Treatment plans should be made in conjunction with the differences in the pathogenesis and treatment of
most important member of the team—the patient—and hypertension.
their support system. By effectively educating patients A challenge in the management of hypertension is the
and their family, long-term compliance and adherence, follow-up of numerous patients. The field of digital
as well as early detection of changes in blood pressure, health, combining digital technologies and health care, is
are likely to be more successful. expanding rapidly and can improve different aspects of
The efforts of controlling blood pressure, along with the blood pressure management. The use of mobile health
other modifiable cardiovascular risk factors, ultimately applications are especially promising self-management
serve to reduce cardiovascular risk by preventing the tools, although not yet fully developed for hypertension.
progression of vascular damage. Conventional 10-year This technology not only provides information on home
risk prediction models identify individuals who would blood pressure measurements but also promotes lifestyle
benefit from therapy over the relative short term, whereas changes by giving advice on physical activity and healthy
cardiovascular risk estimations over a lifetime might be diet, and sending medication reminders.106–108 By actively
better suited to younger individuals who have a longer involving the patient, improved detection and manage
cumulative exposure to elevated blood pressure but a low ment of hypertension can be obtained, with promising
10-year cardiovascular risk. While awaiting evidence to opportunities for resource-limited settings.109 However,
establish the role of lifetime risk in treatment decisions, it further research is needed to identify effective strategies
is important to recognise that early implementation of for the wide implementation of evidence-based digital
preventative measures in younger patients might be health in this field.110
delayed with use of conventional 10-year risk prediction Machine learning and deep learning, two components
models. However, this subset of the population is likely to of artificial intelligence, are being increasingly used in
have the most success in maintaining a low-risk status the management of chronic diseases; however, they
and having a life free from cardiovascular disease, remain underexplored in the field of hypertension. More
by reducing cumulative exposure to elevated blood knowledge is needed on how to implement artificial
pressure.99–102 Older individuals, who are already at an intelligence in risk prediction, accuracy of blood pressure
elevated risk, are more likely to receive treatment but are measurement, treatment decisions, and management of
less likely to capture long-term benefits due to their age. patients with hypertension. Artificial intelligence will
also become an important tool for guiding clinical trials,
Future perspectives contributing to further development and implementation
For a largely controllable condition, the rates of awareness, of precision medicine.
treatment, and control of hypertension are disappointingly Contributors
low. There is room for improvement among the various SB designed the Seminar and coordinated the writing process, with input
levels of health care and throughout the process of patient from EMS. The epidemiology and pathophysiology sections were written
by YK, EMS, and SB. The diagnosis section was written by IS, EMS, and
screening, diagnosis, treatment, and follow-up. Previous SB. In the treatment section, the subsections on non-pharmacological
initiatives have reviewed the necessary actions to improve and pharmacological management of hypertension and timescales of
management of blood pressure worldwide.44 treatment and follow-up were written by EMS and SB, and the subsection
Medications available for hypertension management on device-based treatment was written by IS, SB, and EMS. The section
on future perspectives was written by SB and EMS. All authors
have not changed profoundly throughout previous participated in the literature search. SB and EMS produced the figures
decades. Excitingly, as more has been learned about the and entirely revised all versions of the manuscript. All authors approved
central regulation of blood pressure, a first-in-class the final version for publication.
Declaration of interests 19 Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune
IS reports consulting fees, speaker fees, and travel grants from Amgen, mechanisms of hypertension. Nat Rev Immunol 2019; 19: 517–32.
AstraZeneca, Boston Scientific, Daiichi Sankyo, Medtronic, Novartis, 20 Rodriguez-Iturbe B, Pons H, Johnson RJ. Role of the immune
Recordati, Sanofi, and Servier. All other authors declare no competing system in hypertension. Physiol Rev 2017; 97: 1127–64.
interests. 21 Marques FZ, Mackay CR, Kaye DM. Beyond gut feelings: how the gut
microbiota regulates blood pressure. Nat Rev Cardiol 2018; 15: 20–32.
Acknowledgments
22 Vallianou NG, Geladari E, Kounatidis D. Microbiome and
We thank H Zekollari for the fruitful discussions and help with the hypertension: where are we now? J Cardiovasc Med (Hagerstown)
design of figure 2. YK is supported by the Intramural Research Fund for 2020; 21: 83–88.
the National Cerebral and Cardiovascular Center (20–4–9), Osaka, Japan. 23 Muñoz Aguilera E, Suvan J, Buti J, et al. Periodontitis is associated
References with hypertension: a systematic review and meta-analysis.
1 Stanaway JD, Afshin A, Gakidou E, et al. Global, regional, Cardiovasc Res 2020; 116: 28–39.
and national comparative risk assessment of 84 behavioural, 24 Kokubo Y, Padmanabhan S, Iwashima Y, Yamagishi K, Goto A.
environmental and occupational, and metabolic risks or clusters of Gene and environmental interactions according to the components
risks for 195 countries and territories, 1990–2017: a systematic of lifestyle modifications in hypertension guidelines.
analysis for the Global Burden of Disease Study 2017. Lancet 2018; Environ Health Prev Med 2019; 24: 19.
392: 1923–94. 25 Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel
2 Forouzanfar MH, Liu P, Roth GA, et al. Global burden of pathways influence blood pressure and cardiovascular disease risk.
hypertension and systolic blood pressure of at least Nature 2011; 478: 103–09.
110 to 115 mm Hg, 1990–2015. JAMA 2017; 317: 165–82. 26 Warren HR, Evangelou E, Cabrera CP, et al. Genome-wide association
3 Beaney T, Schutte AE, Stergiou GS, et al. May measurement month analysis identifies novel blood pressure loci and offers biological
2019: The Global Blood Pressure Screening Campaign of the insights into cardiovascular risk. Nat Genet 2017; 49: 403–15.
International Society of Hypertension. Hypertension 2020; 76: 333–41. 27 Evangelou E, Warren HR, Mosen-Ansorena D, et al. Genetic
4 Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and analysis of over 1 million people identifies 535 new loci associated
control of hypertension in China: data from 1·7 million adults in a with blood pressure traits. Nat Genet 2018; 50: 1412–25.
population-based screening study (China PEACE Million Persons 28 Furuhashi M, Moniwa N, Takizawa H, Ura N, Shimamoto K.
Project). Lancet 2017; 390: 2549–58. Potential differential effects of renin-angiotensin system inhibitors
5 Noubiap JJ, Essouma M, Bigna JJ, Jingi AM, Aminde LN, on SARS-CoV-2 infection and lung injury in COVID-19.
Nansseu JR. Prevalence of elevated blood pressure in children and Hypertens Res 2020; 43: 837–40.
adolescents in Africa: a systematic review and meta-analysis. 29 Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–
Lancet Public Health 2017; 2: e375–86. aldosterone system inhibitors and risk of covid-19. N Engl J Med
6 Colhoun HM, Hemingway H, Poulter NR. Socio-economic status 2020; 382: 2441–48.
and blood pressure: an overview analysis. J Hum Hypertens 1998; 30 Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G.
12: 91–110. Renin-angiotensin-aldosterone system blockers and the risk of
7 Ibrahim MM, Damasceno A. Hypertension in developing countries. COVID-19. N Engl J Med 2020; 382: 2431–40.
Lancet 2012; 380: 611–19. 31 Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular
8 Hardy ST, Holliday KM, Chakladar S, et al. Heterogeneity in blood disease, drug therapy, and mortality in COVID-19. N Engl J Med
pressure transitions over the life course: age-specific emergence of 2020; 382: e102.
racial/ethnic and sex disparities in the united states. JAMA Cardiol 32 Mehta N, Kalra A, Nowacki AS, et al. Association of use of
2017; 2: 653–61. angiotensin-converting enzyme inhibitors and angiotensin II
9 Falkner B, Lurbe E. Primordial prevention of high blood pressure in receptor blockers with testing positive for coronavirus disease 2019
childhood an opportunity not to be missed. Hypertension 2020; (COVID-19). JAMA Cardiol 2020; 5: 1020–26.
75: 1142–50. 33 de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin-
10 Kavey R-EW, Daniels SR, Lauer RM, Atkins DL, Hayman LL, angiotensin-aldosterone system inhibitors and risk of COVID-19
Taubert K. American Heart Association guidelines for primary requiring admission to hospital: a case-population study. Lancet
prevention of atherosclerotic cardiovascular disease beginning in 2020; 395: 1705–14.
childhood. Circulation 2003; 107: 1562–66. 34 Son M, Seo J, Yang S. Association between renin-angiotensin-
11 Niiranen TJ, Henglin M, Claggett B, et al. Trajectories of blood aldosterone system inhibitors and COVID-19 infection in
pressure elevation preceding hypertension onset: an analysis of the South Korea. Hypertension 2020; 76: 742–49.
Framingham Heart Study original cohort. JAMA Cardiol 2018; 35 Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-
3: 427–31. angiotensin system inhibitors with severity or risk of death in
12 Delgado J, Bowman K, Ble A, et al. Blood pressure trajectories in patients with hypertension hospitalized for coronavirus disease
the 20 years before death. JAMA Intern Med 2018; 178: 93–99. 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol 2020;
13 Carey RM, Muntner P, Bosworth HB, Whelton PK. Prevention and 5: 825–30.
control of hypertension: JACC Health Promotion Series. 36 Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting
J Am Coll Cardiol 2018; 72: 1278–93. enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.
14 Taddei S, Bruno RM, Masi S, Solini A. Epidemiology and Nat Med 2005; 11: 875–79.
pathophysiology of hypertension. In: Camm AJ, Lüscher TF, 37 Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA,
Maurer G, Serruys PW, eds. The ESC textbook of cardiovascular Solomon SD. Renin-angiotensin-aldosterone system inhibitors in
medicine. Oxford: Oxford University Press, 2018: 2377–88. patients with COVID-19. N Engl J Med 2020; 382: 1653–59.
15 Haikerwal A, Doyle LW, Cheung MM, et al. High blood pressure in 38 Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA
young adult survivors born extremely preterm or extremely low Statement addresses concerns re: using RAAS antagonists in
birthweight in the post surfactant era. Hypertension 2020; 75: 211–17. COVID-19. J Card Fail 2020; 26: 370.
16 Kanda T, Murai-Takeda A, Kawabe H, Itoh H. Low birth weight 39 De Simone G. Position statement of the ESC council on
trends: possible impacts on the prevalences of hypertension and hypertension on ACE-inhibitors and angiotensin receptor blockers.
chronic kidney disease. Hypertens Res 2020; 43: 859–68. March 13, 2020. https://www.escardio.org/Councils/Council-on-
17 Münzel T, Sørensen M, Gori T, et al. Environmental stressors and Hypertension-(CHT)/News/position-statement-of-the-esc-council-
cardio-metabolic disease: part I-epidemiologic evidence supporting on-hypertension-on-ace-inhibitors-and-ang (accessed Oct 25, 2020).
a role for noise and air pollution and effects of mitigation strategies. 40 Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood
Eur Heart J 2017; 38: 550–56. pressure measurement in humans and experimental animals:
18 Fuks KB, Weinmayr G, Basagaña X, et al. Long-term exposure to part 1: blood pressure measurement in humans: a statement for
ambient air pollution and traffic noise and incident hypertension in professionals from the Subcommittee of Professional and Public
seven cohorts of the European study of cohorts for air pollution Education of the American Heart Association Co. Circulation 2005;
effects (ESCAPE). Eur Heart J 2017; 38: 983–90. 111: 697–716.
41 Sharman JE, Marwick TH. Accuracy of blood pressure monitoring 60 Salvetti M, Paini A, Aggiusti C, et al. Unattended versus attended
devices: a critical need for improvement that could resolve blood pressure measurement. Hypertension 2019; 73: 736–42.
discrepancy in hypertension guidelines. J Hum Hypertens 2019; 61 Cushman WC, Evans GW, Byington RP, et al. Effects of intensive
33: 89–93. blood-pressure control in type 2 diabetes mellitus. N Engl J Med
42 Picone DS, Deshpande RA, Schultz MG, et al. Nonvalidated home 2010; 362: 1575–85.
blood pressure devices dominate the online marketplace in 62 Bangalore S, Toklu B, Gianos E, et al. Optimal systolic blood
Australia: major implications for cardiovascular risk management. pressure target after SPRINT: insights from a network meta-
Hypertension 2020; 75: 1593–99. analysis of randomized trials. Am J Med 2017; 130: 707–19.
43 Padwal R, Campbell NRC, Schutte AE, et al. Optimizing observer 63 Blood Pressure Lowering Treatment Trialists' Collaboration.
performance of clinic blood pressure measurement: a position Pharmacological blood pressure lowering for primary and
statement from the Lancet Commission on Hypertension Group. secondary prevention of cardiovascular disease across different
J Hypertens 2019; 37: 1737–45. levels of blood pressure: an individual participant-level data meta-
44 Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse analysis. Lancet 2021; 397: 1625–36.
strategy to address the global burden of raised blood pressure on 64 Sudano I, Beuschlein F, Lüscher TF. Secondary causes of
current and future generations: the Lancet Commission on hypertension. In: Camm AJ, Lüscher TF, Maurer G, Serruys PW,
hypertension. Lancet 2016; 388: 2665–712. eds. The ESC Textbook of Cardiovascular Medicine, 3rd edit.
45 Picone DS, Padwal R, Campbell NRC, et al. How to check whether a Oxford: Oxford University Press, 2018: 2409–19.
blood pressure monitor has been properly validated for accuracy. 65 Gibbs J, Gaskin E, Ji C, Miller MA, Cappuccio FP. The effect of
J Clin Hypertens (Greenwich) 2020; 22: 2167–74. plant-based dietary patterns on blood pressure: a systematic review
46 Campbell NRC, Khalsa T, Ordunez P, et al. Brief online certification and meta-analysis of controlled intervention trials. J Hypertens 2020;
course for measuring blood pressure with an automated blood 39: 23–37.
pressure device. A free new resource to support World Hypertension 66 Kim J, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships
Day Oct 17, 2020. J Clin Hypertens (Greenwich) 2020; 22: 1754–56. between insulin resistance and endothelial dysfunction. Circulation
47 Stergiou GS, Alpert B, Mieke S, et al. A universal standard for the 2006; 113: 1888–904.
validation of blood pressure measuring devices: Association for the 67 Jones NR, McCormack T, Constanti M, McManus RJ. Diagnosis and
Advancement of Medical Instrumentation/European Society of management of hypertension in adults: NICE guideline
Hypertension/International Organization for Standardization update 2019. Br J Gen Pract 2020; 70: 90–91.
(AAMI/ESH/ISO) Collaboration Statement. J Hypertens 2018; 68 Lederle FA, Cushman WC, Ferguson RE, Brophy MT, Fiore Md LD.
36: 472–78. Chlorthalidone versus hydrochlorothiazide: a new kind of veterans
48 Williams B, Mancia G, Spiering W, et al. 2018 practice guidelines affairs cooperative study. Ann Intern Med 2016; 165: 663–64.
for the management of arterial hypertension of the European 69 Chow CK, Thakkar J, Bennett A, et al. Quarter-dose quadruple
society of cardiology and the European society of hypertension combination therapy for initial treatment of hypertension: placebo-
ESC/ESH task force for the management of arterial hypertension. controlled, crossover, randomised trial and systematic review. Lancet
Eur Heart J 2018; 39: 3021–104. 2017; 389: 1035–42.
49 Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ 70 Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke
ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the statistics—2020 update: a report from the American Heart
prevention, detection, evaluation, and management of high blood Association. Circulation 2020; 141: e139–596.
pressure in adults: a report of the American College of Cardiology/
71 Wright JTJ Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive
American Heart Association Task Force on clinical practice
Black and non-Black patients treated with chlorthalidone,
guidelines. J Am Coll Cardiol 2018; 71: e127–248.
amlodipine, and lisinopril. JAMA 2005; 293: 1595–608.
50 Unger T, Borghi C, Charchar F, et al. 2020 International Society of
72 Sulaica EM, Wollen JT, Kotter J, Macaulay TE. A review of
Hypertension global hypertension practice guidelines. Hypertension
hypertension management in Black male patients. Mayo Clin Proc
2020; 75: 1334–57.
2020; 95: 1955–63.
51 Stergiou GS, Palatini P, Parati G et al. 2021 European Society of
73 Ojji DB, Mayosi B, Francis V, et al. Comparison of dual therapies
Hypertension practice guidelines for office and out-of-office blood
for lowering blood pressure in Black Africans. N Engl J Med 2019;
pressure measurement. J Hypertens 2021; published online March 11.
380: 2429–39.
https://doi.org/10.1097/HJH.0000000000002843.
74 Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of
52 Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski J.
angioedema associated with enalapril. Arch Intern Med 2005;
Measurement of blood pressure in the office: recognizing the
165: 1637–42.
problem and proposing the solution. Hypertension 2010;
55: 195–200. 75 Kario K, Chen C-H, Park S, et al. Consensus document on
improving hypertension management in Asian patients, taking into
53 Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial
account Asian characteristics. Hypertension 2018; 71: 375–82.
of intensive versus standard blood-pressure control. N Engl J Med
2015; 373: 2103–16. 76 Sinnott S-J, Tomlinson LA, Root AA, et al. Comparative
effectiveness of fourth-line anti-hypertensive agents in resistant
54 Wohlfahrt P, Cifkova R, Krajcoviechova A, et al. Unattended
hypertension: a systematic review and meta-analysis.
automated office blood pressure measurement. Does it differ from
Eur J Prev Cardiol 2017; 24: 228–38.
office blood pressure? Insight from a random population sample.
J Hypertens 2019; 37: e67. 77 Williams B, MacDonald TM, Morant S, et al. Spironolactone versus
placebo, bisoprolol, and doxazosin to determine the optimal
55 Irigoyen M-C, De Angelis K, Dos Santos F, Dartora DR,
treatment for drug-resistant hypertension (PATHWAY-2):
Rodrigues B, Consolim-Colombo FM. Hypertension, blood pressure
a randomised, double-blind, crossover trial. Lancet 2015;
variability, and target organ lesion. Curr Hypertens Rep 2016; 18: 31.
386: 2059–68.
56 McMullan CJ, Bakris GL, Phillips RA, Forman JP. Association of
78 van der Wardt V, Harrison JK, Welsh T, Conroy S, Gladman J.
BP variability with mortality among African Americans with CKD.
Withdrawal of antihypertensive medication: a systematic review.
Clin J Am Soc Nephrol 2013; 8: 731–38.
J Hypertens 2017; 35: 1742–49.
57 Sega R, Corrao G, Bombelli M, et al. Blood pressure variability and
79 Ji H, Kim A, Ebinger JE, et al. Sex differences in blood pressure
organ damage in a general population: results from the PAMELA
trajectories over the life course. JAMA Cardiol 2020; 5: 19–26.
study (Pressioni Arteriose Monitorate E Loro Associazioni).
Hypertension 2002; 39: 710–14. 80 Bromfield SG, Bowling CB, Tanner RM, et al. Trends in hypertension
prevalence, awareness, treatment, and control among US adults
58 Lonn EM, Bosch J, López-Jaramillo P, et al. Blood-pressure lowering
80 years and older, 1988–2010. J Clin Hypertens (Greenwich) 2014;
in intermediate-risk persons without cardiovascular disease.
16: 270–76.
N Engl J Med 2016; 374: 2009–20.
81 Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific
59 Keeley EC, Villanueva M, Chen YE, et al. Attended vs unattended
relevance of usual blood pressure to vascular mortality: a meta-
systolic blood pressure measurement: a randomized comparison in
analysis of individual data for one million adults in 61 prospective
patients with cardiovascular disease. J Clin Hypertens (Greenwich)
studies. Lancet 2002; 360: 1903–13.
2020; 22: 1987–92.
82 Baker WL, Buckley LF, Kelly MS, et al. Effects of sodium-glucose 96 Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive
cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: treatment strategies and therapeutic inertia evidence from a large
a systematic review and meta-analysis. J Am Heart Assoc 2017; population-based cohort. Hypertension 2018; 72: 846–53.
6: e005686. 97 Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension:
83 Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of detection, evaluation, and management a scientific statement from
sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the- the American Heart Association. Hypertension 2018; 72: e53–90.
art review. JACC Basic Transl Sci 2020; 5: 632–44. 98 Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J.
84 Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal Measuring, analyzing, and managing drug adherence in resistant
sympathetic denervation for resistant hypertension: a multicentre hypertension. Hypertension 2013; 62: 218–25.
safety and proof-of-principle cohort study. Lancet 2009; 373: 1275–81. 99 Ma Y, Wolters FJ, Chibnik LB, et al. Variation in blood pressure and
85 Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, long-term risk of dementia: a population-based cohort study.
Böhm M. Renal sympathetic denervation in patients with PLoS Med 2019; 16: e1002933.
treatment-resistant hypertension (The SYMPLICITY HTN-2 Trial): 100 Zhang Y, Vittinghoff E, Pletcher MJ, et al. Associations of blood
a randomised controlled trial. Lancet 2010; 376: 1903–09. pressure and cholesterol levels during young adulthood with
86 Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal later cardiovascular events. J Am Coll Cardiol 2019; 74: 330–41.
denervation for resistant hypertension. N Engl J Med 2014; 101 Satoh M, Ohkubo T, Asayama K, et al. Lifetime risk of stroke and
370: 1393–401. coronary heart disease deaths according to blood pressure level:
87 Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal EPOCH-JAPAN (Evidence for Cardiovascular Prevention From
denervation in patients with uncontrolled hypertension in the Observational Cohorts in Japan). Hypertension 2019; 73: 52–59.
absence of antihypertensive medications (SPYRAL HTN-OFF MED): 102 Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of
a randomised, sham-controlled, proof-of-concept trial. Lancet 2017; blood pressure to cognitive function and dementia. Lancet Neurol
390: 2160–70. 2005; 4: 487–99.
88 Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based 103 Ferdinand KC, Balavoine F, Besse B, et al. Efficacy and safety of
renal denervation in the absence of antihypertensive medications firibastat, a first-in-class brain aminopeptidase A inhibitor,
(SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, in hypertensive overweight patients of multiple ethnic origins.
sham-controlled trial. Lancet 2020; 395: 1444–51. Circulation 2019; 140: 138–46.
89 Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation 104 Unger T, Steckelings UM, Dzau VJ. The protective arm of the renin
on blood pressure in the presence of antihypertensive drugs: angiotensin system (RAS): functional aspects and therapeutic
6-month efficacy and safety results from the SPYRAL HTN-ON MED implications. London: Elsevier, 2015.
proof-of-concept randomised trial. Lancet 2018; 391: 2346–55. 105 Medina D, Mehay D, Arnold AC. Sex differences in cardiovascular
90 Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound actions of the renin-angiotensin system. Clin Auton Res 2020;
renal denervation to treat hypertension (RADIANCE-HTN SOLO): 30: 393–408.
a multicentre, international, single-blind, randomised, 106 Lu X, Yang H, Xia X, et al. Interactive mobile health intervention
sham-controlled trial. Lancet 2018; 391: 2335–45. and blood pressure management in adults: a meta-analysis of
91 Kandzari DE, Mahfoud F, Bhatt DL, et al. Confounding factors in randomized controlled trials. Hypertension 2019; 74: 697–704.
renal denervation trials: revisiting old and identifying new 107 Pellegrini D, Torlasco C, Ochoa JE, Parati G. Contribution of
challenges in trial design of device therapies for hypertension. telemedicine and information technology to hypertension control.
Hypertension 2020; 76: 1410–17. Hypertens Res 2020; 43: 621–28.
92 Heusser K, Thöne A, Lipp A, et al. Efficacy of electrical baroreflex 108 Parati G, Torlasco C, Omboni S, Pellegrini D. Smartphone
activation is independent of peripheral chemoreceptor modulation. applications for hypertension management: a potential game-
Hypertension 2020; 75: 257–64. changer that needs more control. Curr Hypertens Rep 2017; 19: 48.
93 Groenland EH, Spiering W. Baroreflex amplification and carotid 109 WHO. WHO guideline: recommendations on digital interventions
body modulation for the treatment of resistant hypertension. for health system strengthening. Geneva: World Health
Curr Hypertens Rep 2020; 22: 27. Organization, 2019.
94 Brouwers S, Droogmans S, Dolan E, et al. A prospective 110 World Health Assembly. Seventy-first World Health Assembly.
non-randomized open label multi-center study to evaluate the effect of Agenda item 12·4. Digital health. May 26, 2018. https://apps.who.
an iliofemoral arteriovenous fistula on blood pressure in patients with int/gb/ebwha/pdf_files/WHA71/A71_R7-en.pdf (accessed
therapy-resistant hypertension. Eur Heart J 2013; 34 (suppl 1): 3616. Oct 25, 2020).
95 Lobo MD, Sobotka PA, Stanton A, et al. Central arteriovenous
anastomosis for the treatment of patients with uncontrolled © 2021 Elsevier Ltd. All rights reserved.
hypertension (the ROX CONTROL HTN study): a randomised
controlled trial. Lancet 2015; 385: 1634–41.